Rallybio (RLYB) closed at $16.64 on October 23, 2026, up 1.5% from the previous close, on volume of 6,185 shares (30-day average 12,761).
Data as of October 23, 2026.
Globe Newswire (Thu, 22-Oct 6:27 PM ET)
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
Business Wire (Thu, 22-Oct 2:00 PM ET)
Market Chameleon (Mon, 2-Mar 5:29 AM ET)
Market Chameleon (Mon, 2-Mar 4:15 AM ET)
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Rallybio trades on the NASDAQ stock market under the symbol RLYB.
As of October 23, 2026, RLYB stock price climbed to $16.64 with 6,185 million shares trading.
RLYB has a beta of 0.52, meaning it tends to be less sensitive to market movements. RLYB has a correlation of 0.01 to the broad based SPY ETF.
RLYB has a market cap of $88.40 million. This is considered a Micro Cap stock.
In the last 3 years, RLYB traded as high as $36.80 and as low as $1.76.
The top ETF exchange traded funds that RLYB belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFMC.
RLYB has outperformed the market in the last year with a price return of +246.7% while the SPY ETF gained +14.3%. However, in the short term, RLYB had mixed performance relative to the market. It has underperformed in the last 3 months, returning +1.5% vs +3.2% return in SPY. But in the last 2 weeks, RLYB shares have fared better than the market returning -2.2% compared to SPY -2.4%.
RLYB support price is $16.02 and resistance is $16.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLYB shares will trade within this expected range on the day.
